Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2019 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10

Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed.Metastatic...